Individuals with fast nicotine metabolism typically smoke more and thus have a greater risk for smoking-induced diseases. Further, the efficacy of smoking cessation pharmacotherapy is dependent on the rate of nicotine metabolism. Our objective was to use nicotine metabolite ratio (NMR), an established biomarker of nicotine metabolism rate, in a genome-wide association study (GWAS) to identify novel genetic variants influencing nicotine metabolism. A heritability estimate of 0. 81 (95% CI 0. 70–0. 88) was obtained for NMR using monozygotic and dizygotic twins of the FinnTwin cohort. We performed a GWAS in cotinine-verified current smokers of three Finnish cohorts (FinnTwin, Young Finns Study, FINRISK2007), followed by a meta-analysis of 1518 subjects, and annotated the genome-wide significant SNPs with methylation quantitative loci (meQTL) analyses. We detected association on 19q13 with 719 SNPs exceeding genome-wide significance within a 4. 2 Mb region. The strongest evidence for association emerged for CYP2A6 (min p = 5. 77E-86, in intron 4), the main metabolic enzyme for nicotine. Other interesting genes with genome-wide significant signals included CYP2B6, CYP2A7, EGLN2, and NUMBL. Conditional analyses revealed three independent signals on 19q13, all located within or in the immediate vicinity of CYP2A6. A genetic risk score constructed using the independent signals showed association with smoking quantity (p = 0. 0019) in two independent Finnish samples. Our meQTL results showed that methylation values of 16 CpG sites within the region are affected by genotypes of the genome-wide significant SNPs, and according to causal inference test, for some of the SNPs the effect on NMR is mediated through methylation. To our knowledge, this is the first GWAS on NMR. Our results enclose three independent novel signals on 19q13. 2. The detected CYP2A6 variants explain a strikingly large fraction of variance (up to 31%) in NMR in these study samples. Further, we provide evidence for plausible epigenetic mechanisms influencing NMR.
Nicotine is a neuro-stimulant with high addiction potential [1]. Similar to other drugs causing dependence, nicotine increases dopamine levels in the nucleus accumbens and activates the mesolimbic brain reward pathway [2]. Nicotine metabolism rate varies significantly between individuals and is strongly correlated to total nicotine clearance thus altering nicotine levels from a given intake [3]. Smokers are known to titrate their nicotine levels via cigarette consumption, number and volume of puffs, and depth of inhalation, to achieve and maintain desired levels; thus, nicotine clearance rate influences smoking behavior [4]. Individuals with fast metabolism typically smoke more, are less likely to succeed in quitting, and are more prone to nicotine dependence (ND) [5]. Consequently, those who smoke more have a greater risk for smoking-induced diseases [6]. Beyond the evident toxic effects of tobacco smoke, there is increasing evidence that, in addition to the known acute effects of nicotine [7], chronic nicotine exposure as such may also increase the risk of cancer by multiple mechanisms [8]. With the advent of other nicotine delivery devices than tobacco, such as e-cigarettes, the need to understand the long-term consequences and action mechanisms of nicotine and its metabolism are of high public health relevance. A member of the cytochrome P450 family, CYP2A6, is the main metabolic enzyme for nicotine accounting for up to 80% of nicotine clearance [9]. A large number of distinct CYP2A6 (ENSG00000255974) alleles have been identified, including SNPs, duplications, deletions, and conversions (www. cypalleles. ki. se/cyp2a6. htm). CYP2A6 variations have been phenotypically grouped as slow (<50% of activity), intermediate (80% of activity), and normal (100% of activity) metabolizers. Another member of the cytochrome P450 family, CYP2B6, has an approximately 10% catalytic efficiency of the CYP2A6 enzyme in vitro in nicotine c-oxidation, and may play a minor role in nicotine clearance at higher nicotine levels [10] or in the absence of functional CYP2A6. While CYP2A6 is expressed primarily in the liver, CYP2B6 (ENSG00000197408) is expressed at higher levels in the brain, where it may influence localized metabolism of nicotine [11,12]. Cytochrome P450 drug metabolizing enzymes are rarely highlighted in genome-wide association studies (GWAS) as the allele frequencies of the functional variants are low in most populations [13]. However, in 2010 a very large GWAS meta-analysis of smoking quantity revealed associations of CYP2A6 and CYP2B6 with SNPs that are in strong linkage disequilibrium (LD) with known functional variants [14]. Nicotine metabolism involves multiple steps and several enzymatic pathways. Up to 75% of nicotine is converted to cotinine mainly by CYP2A6,15% of nicotine is metabolized through other metabolic pathways, and a minor fraction (10–15%) is excreted to urine unchanged. The majority of cotinine is further converted to 3-hydroxycotinine exclusively by CYP2A6; up to 40% is excreted to urine as 3-hydroxycotinine while 10% is further metabolized into 3-hydroxycotinine-glucuronide by UGT enzymes prior to excretion. Approximately 15% of cotinine is converted to cotinine-glucuronide by UGT enzymes, and the remaining is metabolized through other pathways. [9] Cotinine is a relatively stable compound with a half-life of 15–20h, and is superior as a biomarker of nicotine intake compared to self-reported smoking quantity (cigarettes per day, CPD) [15]. The ratio of 3-hydroxycotinine/cotinine (i. e. nicotine metabolite ratio, NMR) is an established biomarker of CYP2A6 activity, as well as nicotine metabolism rate, and it correlates strongly with total nicotine clearance [3]. Twin studies suggest an important genetic contribution to nicotine metabolism, measured using the nicotine metabolite ratio. Swan and colleagues reported that the estimated additive genetic effects on plasma NMR were 0. 67 (95% CI 0. 56–0. 76), dropped to 0. 61 (95% CI 0. 48–0. 71) after adjusting for non-genetic covariates, and further reduced to 0. 49 (95% CI 0. 33–0. 63) when CYP2A6 was adjusted for [16], suggesting that known CYP2A6 variants identified at the time accounted for approximately 15–20% of NMR heritability. In addition to the strong effect of CYP2A6 and other genetic influences, NMR is also influenced by various demographic and hormonal factors. According to a recent study [17], factors affecting NMR include ethnicity, likely due to the varying frequency of reduced activity CYP2A6 variants among different ethnicities [13]. Other affecting factors include sex, hormone replacement therapy, and use of estrogen containing contraceptive pills, all related to CYP2A6 being induced by estrogen [18], as well as body mass index (BMI), alcohol consumption, and cigarette consumption [17]. Altogether these above mentioned factors were estimated to account for approximately 8% of inter-individual variance in NMR [17]. In addition to significantly affecting smoking behavior, nicotine clearance rate has been shown to contribute to the efficacy of cessation pharmacotherapy in various retrospective studies [19–21]. In a recent randomized prospectively NMR-stratified placebo-controlled clinical trial, varenicline (a prescription medication for smoking cessation) was more efficacious for normal metabolizers compared to nicotine patch [22]. Nicotine patch was equally effective in slow metabolizers with less side-effects than in varenicline treatment, suggesting that tailored pharmacotherapy, i. e. stratifying on NMR level, can be one approach for improving smoking cessation rates [22]. This first clinical trial to take nicotine metabolism rate into account is a landmark paper highlighting the importance of the metabolic component cigarette smoking and use of other nicotine products. GWAS using metabolites measured from serum have been highly successful in identifying underlying genes [23,24], highlighting the power of informative phenotypes. Our objective was to utilize NMR, a genetically informed biomarker of nicotine metabolism, in a GWAS meta-analysis of cotinine-verified (≥10ng/ml) current smokers from three Finnish cohorts to identify novel genetic variants influencing nicotine metabolism rate. In Caucasians, with up to 90% of individuals being normal metabolizers, a minor fraction of variance in inter-individual differences in nicotine metabolism is accounted for by known reduced activity CYP2A6 variants. Thus, we expected that other contributing factors, such as other genes, but also novel regulators of CYP2A6 action or expression, including epigenetic mechanisms, are bound to exist. Our data highlighted novel genetic and epigenetic influences on NMR, deepening our understanding on factors influencing nicotine metabolism and providing valuable guidelines for further focused studies.
Written informed consent, according to the current edition of the Declaration of Helsinki, was obtained from all subjects who were interviewed and/or gave DNA samples before the beginning of the studies. The collection of blood samples followed the recommendations given in the Declaration of Helsinki and its amendments. For the FinnTwin12, FinnTwin16, and NAG-FIN studies, data collection has been approved by the hospital district of Helsinki and Uusimaa, the ethics committee for epidemiology and public health (HUS-113-E3-01, HUS-346-E0-05, HUS 136/E3/01). FinnTwin12 and FinnTwin16 have also been approved by the IRB of Indiana University at Bloomington, Indiana, while NAG-FIN was also approved by the IRB of Washington University (St. Louis). Young Finns Study data collection has been approved by the hospital district of Southwest Finland ethics committee (ETMK: no. 88/180/2010). The ethics approvals for FINRISK have been obtained from the Coordinating Ethics Committee of Helsinki and Uusimaa Hospital District. Cotinine and 3-hydroxycotinine phenotypes were measured from frozen serum samples using liquid chromatography/tandem mass spectrometry (University of Toronto, prof. Rachel Tyndale’s laboratory) for the FinnTwin12, FinnTwin16, and YFS samples, as previously described [33], and using gas chromatograph-mass spectrometer (at the National Institute for Health and Welfare, Helsinki, Finland) for the FINRISK2007 sample, as previously described [34]; these assays for NMR were demonstrated to be fully concordant (R2 = 0. 93, P<0. 0001) [35]. Cotinine threshold of ≥10ng/ml was applied to restrict the analyses to regular smokers. Several potential factors influencing on NMR (sex, age, BMI, smoking quantity, alcohol consumption, genotyping batch) [17] were considered as covariates. Sex and BMI were associated with NMR (p<0. 05) in the initial linear univariate regression models, and were selected as covariates for the study specific GWAS. Further, age was selected as a covariate due to the sampling design of the population-based samples. Neither smoking quantity, alcohol consumption, nor genotyping batch, were significant confounders (p>0. 05) and thus were not included as covariates. Details of phenotype and covariate distributions in the three samples are presented in Table 1. Genotyping was performed with the Human670-QuadCustom Illumina BeadChip at the Welcome Trust Sanger Institute, and with the Illumina Human Core Exome BeadChip at the Welcome Trust Sanger Institute and at the Broad Institute of MIT and Harvard. Standard post-genotyping quality control thresholds were applied for SNPs (minor allele frequency (MAF) <0. 01, SNP call rate <0. 95, and Hardy Weinberg Equilibrium (HWE) p<1E-06). Further, subjects with a call rate <0. 95 were excluded, and a sample heterozygosity test, as well as sex and Multidimensional Scaling (MDS) outlier checks were done. Pre-phasing of the data was done with SHAPEIT2 [36] and imputation with IMPUTE2 [37] using the 1000 Genomes Phase I integrated haplotypes (produced using SHAPEIT2) reference panel [38]. For data generated with the Human670-QuadCustom Illumina BeadChip the following post-imputation exclusion criteria were applied for SNPs: MAF<0. 01, SNP call rate <0. 95 (<0. 99 for SNPs with MAF<0. 05), HWE p<1E-06, and imputation info <0. 4. For data generated with the Illumina Human Core Exome BeadChip the SNP exclusion criteria were otherwise identical, except that a threshold of minor allele count <2 was applied instead of a MAF cut-off. Further, the same sample quality thresholds as in post-genotyping quality control were applied. Quality controls and imputation for all Finnish GWAS data were done centrally at the Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland.
MZ and DZ twins of the FinnTwin12 and FinnTwin16 cohorts were used to provide heritability estimates for NMR. The intraclass correlation for NMR was 0. 80 for MZ and 0. 26 for DZ pairs. The pattern of correlations suggested that in addition to additive genetic effects, dominance effects may be present but shared environmental were unlikely to be present. The data were consistent with both AE and ADE models, but not the ACE model as the MZ correlation was much larger than twice the DZ correlation (in such a situation the C component will be zero). In the AE model, A effects accounted for 0. 81 (95% CI 0. 70–0. 88) of variance in NMR. The ADE model fit difference was not statistically significant from the more parsimonious AE model (p = 0. 087, Δχ2 = 2. 94, Δdf = 1); in the ADE model A effects accounted for 0. 20 (95%CI 0. 00–0. 85) and D effects for 0. 62 (95%CI 0. 00–0. 88) of the variance in NMR. According to the power analyses we had inadequate power to detect signals with rare SNPs (MAF <5%) unless they have very large effect sizes, but high power to detect signals with common SNPs (MAF >5%) that have medium to high effect sizes (beta>±0. 6) (S1 Table). Each of the three Finnish cohorts independently showed genome-wide significant association on 19q13. 2. In our GWAS meta-analysis 719 SNPs exceeded the genome-wide significance threshold within a 4. 2 Mb region on 19q13. 2 (chr19: 39546965–43710562; according to GRCh37/hg19) (S2 Table). Manhattan and QQ plots are presented in Figs 1 and 2. The strongest evidence for association emerged for CYP2A6 (minimum p = 5. 77E-86 for rs56113850, in intron 4) (S3 Table). Other genes of relevance with genome-wide significant signals included CYP2B6 (minimum p = 1. 95E-24 for rs7260329, in intron 8), CYP2A7 (ENSG00000198077) (minimum p = 1. 43E-38 for rs28602288, beta = -0. 48, -83C>T, within predicted promoter region), EGLN2 (ENSG00000269858) (minimum p = 7. 87E-16 for rs76443752, in intron 3), and NUMBL (ENSG00000105245) (minimum p = 1. 40E-20 for rs4802082, in intron 5) (S2 Table). Conditional analyses of the 19q13. 2 locus revealed three independent genome-wide significant signals tagged by rs56113850, rs113288603, and esv2663194 (Fig 3 and Table 2). The same independent SNPs emerged in all the three cohorts. A fourth independent signal (rs12461964) emerged in the conditional analysis of the FINRISK2007 sample; however, this was not seen in the meta-analysis of the three samples. All the independent SNPs are imputed, and are located either within CYP2A6 or at most at a distance of 8 kb from the gene. For all the independent SNPs the minor allele decreases NMR, i. e. decreases nicotine clearance rate (Table 2). None of the independent SNPs have predicted functional effects. A plausible interplay between the top-SNP rs56113850 and rs113288603 was detected. When analysed within the largest of our cohorts (YFS) the minor allelic effect size of rs113288603 increased from non-significant (beta = 0. 05, p = 0. 522) to highly significant (beta = -0. 47, p = 1. 32E-09) when rs56113850 was added to the model; when an interaction term (rs56113850*rs113288603) was also added to the model the effect size further increased (beta = -0. 62, p = 1. 32E-03). Similarly, the effect size of rs56113850 increased from -0. 67 (p<2E-16) to -0. 83 (p<2E-16) when rs113288603 was added to the model; addition of an interaction term (rs56113850*rs113288603) to the model did not further affect the results (beta = -0. 82, p<2E-16). According to LD estimation in the large FINRISK sample (N = 19857), rs56113850 and rs12461964 share an LD block with the known reduced activity allele CYP2A6*2, and esv2663194 shares a block with the known reduced activity allele CYP2A6*9, while rs113288603 is located outside these LD blocks (S5 Fig). Based on pairwise LD values both CYP2A6*2 and CYP2A6*9 exhibit strong LD with all four independent SNPs (S4 Table), and after conditioning on the top-SNP (rs56113850) neither were genome-wide significant (S5 Table). Age, sex, and BMI explained altogether 8. 9%, 6. 1%, and 0. 53% of the variance in NMR in FinnTwin, YFS, and FINRISK2007 samples, respectively. The top-SNP rs56113850 alone explains 14–23% of the variance in NMR in the three cohorts (Table 2). Further, the percentage of variance explained by the three independent SNPs (rs56113850, rs113288603, and esv2663194) when jointly included in the model was 20. 8% in FinnTwin, 31. 4% in YFS, and 26. 3% in FINRISK (increasing to 27. 7% when rs12461964 was included). In the wGRS analyses highly similar results were obtained for the 3-SNP and 4-SNP wGRSs; only results for the 4-SNP wGRS are presented. For ease of interpretation, the wGRS was constructed as a weighted sum of major alleles (all of which increase nicotine clearance rate). In the wGRS meta-analysis of 3954 current smokers statistically significant association was detected for quantitative CPD (beta = 0. 10,95% CI 0. 04–0. 16, p = 0. 0019), suggesting that individuals with faster metabolism smoke more. The wGRS meta-analysis for current (N = 3954) vs. former (N = 3543) smoking showed association with increased likelihood of being a former smoker (OR = 1. 39,95% CI 1. 09–1. 76, p = 0. 007). Similarly, the major allele of CYP2A6*2 showed a trend of association with increased likelihood of being a former smoker (OR = 1. 03,95% CI 0. 72–1. 47, p = 0. 89), although the results were not statistically significant. To scrutinize potential confounders for cessation, we utilized available questionnaire data and excluded NAG-FIN individuals who either have a DSM-IV major depression disorder diagnosis or report quitting due to adverse health consequences and FINRISK individuals who have a relevant somatic diagnosis, are on disability pension, or rate their health as ‘poor’. Further, we adjusted the analyses for alcohol consumption. After these exclusions, 2946 current and 2591 former smokers remained, and the wGRS result no longer was statistically significant (OR = 1. 30,95% CI 0. 95–1. 78, p = 0. 10). We also tested these models with the rs56113850*rs113288603 interaction term included as a covariate; in all the models the interaction term was non-significant (p>0. 05) and so a more complex model was not justified. In the meQTL analyses of the 719 genome-wide significant SNPs and 158 CpG sites within the target region, methylation values of 16 CpG sites showed statistically significant association with 173 of the SNPs (FDR corrected p<0. 05) (S6 Table). Among the highlighted genes were EGLN2, CYP2A7, CYP2F1 (Cytochrome P450, Family 2, Subfamily F, Polypeptide 1) (ENSG00000197446), and DLL3 (Delta-like 3 (Drosophila) ) (ENSG00000090932) (S7 Table). To distinguish between our hypotheses B (‘SNPs affect NMR via methylation’) and C (‘SNPs affect methylation via NMR’) we performed CIT, and confirmed that methylation at the CpG site tagged by cg08551532 (in DLL3) mediates the effect of SNPs on NMR (S8 Table). We detected no evidence supporting hypothesis C.
Nicotine metabolism rate is one of the key factors affecting smoking behavior, and has also been shown to contribute to the efficacy of cessation pharmacotherapy [22]. Many smokers find it exceedingly difficult to succeed in quitting, even when they have a major cardiovascular illness and smoking cessation would greatly improve their prognosis [53]. Current pharmacotherapies and behavioral counselling enhance smoking cessation rate on average by only approximately 2-fold [54], highlighting the need for more effective cessation support. Unraveling the genetic architecture of nicotine metabolism may enhance development of tailored smoking cessation pharmacotherapies. MZ and DZ twins of FinnTwin12 and FinnTwin16 cohorts yielded a heritability estimate of 0. 81 for NMR, confirming that genetic effects are major determinants of inter-individual variance in NMR. This estimate is higher than previous estimates obtained in an experimental setting [16], perhaps due to less heterogeneity in the Finnish sample. Our aim was to identify novel genetic variants affecting nicotine metabolism. We utilized NMR, a biomarker of nicotine metabolism, in a GWAS meta-analysis of three Finnish cohorts, and identified association on 19q13. 2. This locus harbours a number of genes, including several members of the cytochrome P450 gene family. Three independent genome-wide significant signals were detected, all located either within or in the immediate vicinity of CYP2A6, the gene encoding the main metabolic enzyme for nicotine. A fourth independent signal in CYP2A6 emerged in one of the samples (FINRISK2007); however, this was not seen in the meta-analysis. The minor alleles of all of the independent variants associated with decreased NMR values, i. e. decreased nicotine clearance rate. All the independent variants are novel signals and have not been previously been highlighted in any smoking-related GWAS. Our top-SNP (rs56113850) is located in intron 4 of CYP2A6, has a high minor allele frequency (MAFFINRISK = 0. 44) and a prominent effect size (beta = -0. 65), and alone accounts for a substantial percentage of variance (14–23%) in NMR in the three Finnish cohorts. Our second independent SNP (rs113288603) is located 5. 9 kb upstream of CYP2A6, seems to be enriched in the Finnish population (MAFFINRISK = 0. 15 vs. MAFEUR = 0. 09), has a small effect size (beta = -0. 02), and accounts for less than 1% of variance in NMR in the three cohorts. Neither of these variants has predicted functional consequences. Interestingly, our data support a plausible interplay between rs113288603 and rs56113850, as the effect sizes significantly increase when the other SNP is added to the model. These findings are in line with our GWAS data, as rs113288603 shows no association in any of the cohort-specific GWAS or in the meta-analysis, but in an analysis conditioned on rs56113850 it emerges as the second independent genome-wide significant SNP. The plausible mechanism underlying the interplay remains to be determined. Our third independent variant (esv2663194) tags a 32 kb deletion that affects both CYP2A6 and CYP2A7. Esv2663194 has a low minor allele frequency (MAFFINRISK = 0. 03) and a prominent effect size (beta = -1. 08), and accounts for 3–8% of variance in NMR in the three cohorts. The 32 kb (chr19: 41355715–41387669, according to GRCh37/hg19) deletion abolishes exons 1–2 in CYP2A6 and exons 2–9 in CYP2A7 when compared to the reference sequence; both genes have multiple isoforms and the consequence of the deletion varies between the isoforms. The 32 kb deletion may produce a similar construct as CYP2A6*12, which is a hybrid allele formed by an unequal crossover between CYP2A6 and CYP2A7. CYP2A6*12 is composed of the 5′-regulatory region and exons 1–2 of CYP2A7 and exons 3–9 and the 3′-regulatory region of CYP2A6, and harbors 10 amino acid differences when compared to the wild-type CYP2A6 allele, with an allele frequency of 2. 2% reported among Spaniards [51]. CYP2A6*12 is shown to have reduced enzyme activity in vivo [55,56]; in line with this, the minor allele of esv2663194 associates with decreased clearance rate. Further studies are needed to confirm whether the 32 kb deletion tagged by esv2663194 indeed creates a construct with properties similar to CYP2A6*12. Our fourth independent SNP (rs12461964; detected in the FINRISK2007 sample) is located 8. 2 kb downstream of CYP2A6, has a high minor allele frequency (MAFFINRISK = 0. 45) and a prominent effect size (beta = -0. 61). Rs12461964 is in high LD with the top-SNP rs56113850 (D’ = 0. 85); although it was identified as an independent SNP in conditional analyses in the FINRISK2007 sample, the detected association likely reflects LD with rs56113850. To date, the most widely studied CYP2A6 variants include CYP2A6*2 (rs1801272, L160H) which encodes a catalytically inactive enzyme, a whole gene deletion allele CYP2A6*4, CYP2A6*9 (rs28399433, -48T>G), which has an alteration in the TATA box resulting in lower expression of a structurally normal protein, and CYP2A6*12 discussed above [13]. Of these characterized reduced-activity variants, our data included CYP2A6*2 and CYP2A6*9, both of which showed genome-wide significant association but were not identified as independent signals in conditional analyses. A previous very large (N = 85997) meta-analysis of self-reported CPD showed genome-wide significant association on 19q13. 2, with strongest evidence obtained for rs4105144, which is in LD with CYP2A6*2 (D′ = 1. 0 in CEU) [14]. Similarly, LD between our novel independent signals and both CYP2A6*2 and CYP2A6*9 was high (D’ = 0. 89–1. 00). The percentage of variance in NMR explained by CYP2A6*2 and CYP2A6*9 in our study cohorts was up to 6% and 12%, respectively. A previous study using an ethnically diverse sample suggested that 15–20% of variance in NMR is accounted for by the four characterized reduced-activity variants (CYP2A6*2, CYP2A6*4, CYP2A6*9, and CYP2A6*12) [16]; much of the genetic variation would not have been tested for in this study (i. e. CYP2A6*10 –*35). Interestingly, in our study CYP2A6*9 alone explained a large fraction of variance in NMR, possibly due to the higher minor allele frequency in the Finnish cohorts (MAF 0. 12–0. 14) compared to that reported in the Caucasian population (MAFEUR = 0. 07). In addition to CYP2A6*2 and CYP2A6*9, our data set included three additional known alleles, CYP2A6*14 (rs28399435; S29N), CYP2A6*18 (rs1809810; Y392F), and CYP2A6*21 (rs6413474; K476R). Although they are non-synonymous variants, their effect on nicotine clearance likely is minimal. CYP2A6*14 does not appear to affect enzyme activity [57,58], and although CYP2A6*18 has a decreased activity towards another substrate, coumarin, activity towards nicotine is unaffected [59]. Based on in vivo studies, CYP2A6*21 showed normal activity in a Caucasian population [60]. After conditioning on our top-SNP (rs56113850), none of the five known alleles were genome-wide significant, suggesting that rs56113850 captures information on all of these alleles. The percentage of variance explained by our novel independent SNPs was very high (up to 31%), exceeding the estimates for the four functional variants frequently genotyped in Caucasians [16]. Our novel variants likely tag multiple functional variants, both known and unidentified ones, and thus capture information on relevant haplotypes. The population-attributable effect of the novel independent variants thus is far greater than that of the known functional variants, and for the purpose of estimating the rate of nicotine metabolism our novel SNPs are more informative than the known previously characterized reduced-activity variants. Based on our twin modelling, the heritability of NMR is 0. 81. Although our novel independent SNPs capture a strikingly large fraction of this, major fraction still remains unaccounted for. This may be due to limitations of GWAS with lack of coverage of CYP2A6 duplications, translocations, and rare variants. Further, the high sequence homology between CYP2A6, CYP2A7, and CYP2A13 may prohibit detection of variants within homologous regions. SNP genotyping technologies using short probes will not be able to detect these variants with high specificity; most likely such variants will fail the HWE threshold, and thus will be excluded from analyses. In addition, limitations of statistical power result in inability to detect all relevant signals. In our GWAS meta-analysis we had high power to detect signals with common SNPs (MAF >5%) that have medium to high effect sizes. This is reflected in our top-SNPs, three of which are not only common but also have large effect sizes, and one that is rare (MAF = 0. 03) but has a large effect size (beta = -1. 08). We had very low power to detect signals with rare SNPs that have low effect sizes, and it is likely that we missed those signals; larger studies are needed to capture these signals. Ethnicity has been reported as a prominent factor affecting NMR; however, all the subjects in the current study were Caucasian (Finns). Age, sex, and BMI accounted for 8. 9% and 6. 1% of variance in NMR in the FinnTwin and YFS samples, respectively. This is in line with a previous study showing that various non-genetic factors account for altogether 8% of inter-individual variance in NMR [17]. However, in the FINRISK2007 sample age, sex, and BMI only accounted for 0. 5% of variance in NMR, which may be due to older age and longer overall duration of smoking with more cessation than among the young adult FinnTwin and YFS samples. Although only variants in CYP2A6 were highlighted as independent signals, other interesting genes, such as CYP2B6, CYP2A7, EGLN2, and NUMBL, reside within the 19q13 locus, and showed genome-wide significant association in our GWAS meta-analysis. Our top-SNP in CYP2B6 (rs7260329) has been highlighted in the large GWAS meta-analysis of CPD [14]. CYP2B6 can also catalyze nicotine metabolism to cotinine and to nornicotine [9]; the CYP2B6 gene sits adjacent to CYP2A6 and they share some common regulation. CYP2B6 also metabolizes several other drugs of abuse, as well as bupropion, an atypical antidepressant also used as a smoking cessation aid [5]. Several functional CYP2B6 variants have been identified. The most prevalent and clinically important variant is CYP2B6*6, characterized as a haplotype consisting of two linked non-synonymous variants CYP2B6*4 (rs2279343 (K262R) ) and CYP2B6*9 (rs3745274 (Q172H) ), resulting in a splice site variant with reduced function [61]. In the current study the non-synonymous SNPs defining CYP2B6*4, CYP2B6*9, as well as CYP2B6*5 (rs3211371 (R487C) ) did not show genome-wide significant results, but were in high LD with the top-SNP in CYP2B6 (rs7260329) (S9 Fig). Further, rs7260329 shows modest LD with our independent SNPs rs56113850 (D’ = 0. 40), esv2663194 (D’ = 0. 65), and rs12461964 (D’ = 0. 43), but not with rs113288603 (D’ = 0. 04); thus, it is unclear whether the detected association simply reflects LD with the independent variants residing in CYP2A6. The interpretation of the detected CYP2A7 association is challenging, as the possible role of CYP2A7 in nicotine metabolism is unknown. Our top SNP in CYP2A7 (rs28602288) is located within a predicted promoter region. It is plausible that the association between rs28602288 and NMR reflects the regulation of CYP2A6*12 (a hybrid allele of CYP2A6 and CYP2A7) or similar constructs, such as the one generated by the 32 kb deletion tagged by esv2663194, rather than implies a role for CYP2A7 in nicotine clearance. Rs28602288 is in LD with all of the independent variants (D’ = 0. 67–1. 00). Two additional interesting genes were highlighted. Egl-9 Family Hypoxia-Inducible Factor 2 (EGLN2) is a key component of the oxygen-sensing pathway that regulates the expression of various downstream genes, and responses e. g. to carbon monoxide (CO) and cigarette smoke exposure. In a recent study, EGLN2 was associated with CPD and breath CO independent of CYP2A6, although it was not associated with nicotine metabolism [62]. The top-SNP in EGLN2 (rs76443752) is in LD with all of the independent CYP2A6 variants (D’ = 0. 67–1. 00). Another potentially interesting candidate is Numb Homolog (Drosophila) -Like (NUMBL) which encodes a protein that maintains progenitor cells during cortical neurogenesis [63] and has previously been implicated in lung cancer [64,65]. The top-SNP in NUMBL (rs4802082) is in LD with all of the independent variants (D’ = 0. 48–0. 96). We constructed wGRS using the independent 19q13. 2 SNPs and tested whether the wGRS predicts smoking behavior in two independent Finnish samples. The wGRS constructed of major alleles (increasing the metabolism rate) was associated with increased smoking quantity. This is in line with previous evidence of faster metabolizers smoking more [66]. Adding the rs56113850*rs113288603 interaction term to the wGRS analyses did not improve model fit, suggesting that the simpler model with main effects was sufficient. Our unadjusted wGRS results for current vs. former smoking suggested that major alleles that associate with faster metabolism associate with increased odds of being a former smoker; after adjustment and exclusion for potential confounders the wGRS result no longer was significant. Although the sample size decreased, the confidence intervals did not significantly increase, suggesting that the change in results is due to reduced confounding rather than reduced power. Many clinical trials and epidemiological studies indicate that slow metabolizers quit more often than normal metabolizers [20,67,68]. Possibly our wGRS does not capture all the relevant aspects of measured NMR or the cross-sectional nature of the FINRISK smoking status data did not permit us to fully replicate earlier findings. We followed up the 719 genome-wide significant SNPs by meQTL analyses in order to annotate their potential functional consequence. As smoking is known to induce significant changes in methylation patterns [69], only cotinine-verified current smokers (cotinine≥10ng/ml) were included in the analyses. Several SNPs showed significant association with methylation values of 16 CpG sites located within the target region. The 16 CpG sites overlap with relevant genes, such as members of the cytochrome P450 gene family (CYP2F1 and CYP2A7) and EGLN2. According to CIT, methylation in one CpG site mediate the effect of SNPs on the variance observed in NMR. This CpG site (tagged by cg08551532) is located in DLL3, which is involved in neurogenesis via its role in the Notch signaling pathway [70]. Further, DLL3 has been shown to be silenced by methylation in human hepatocellular carcinoma (HCC), leading to restricted growth of cancer cells [71]. Expression of NOTCH3, encoding for a receptor for DLL3, has been shown to be influenced by cigarette smoke [72]. The potential mechanism how DLL3 may affect nicotine metabolism remains to be determined. To our knowledge this is the first GWAS of NMR reported to date. Despite a relatively small sample size (N = 1518), we detected a multitude of genome-wide significant signals on 19q13. 2, highlighting the power of informative biomarkers in GWAS and demonstrating the power of Finnish population samples to identify novel genes even with a modest sample size. Our genetic and epigenetic analyses enclosed several genes as potential players in regulating NMR. Four members of the cytochrome P450 gene family (CYP2A6, CYP2B6, CYP2A7, and CYP2F1) were highlighted, although only CYP2A6 encompassed independent signals. Three additional highlighted genes (DLL3, NUMBL, and EGLN2) are functionally linked according to the GeneMania database (http: //www. genemania. org/), suggesting that an interplay between these genes may influence NMR. Future studies are needed to elucidate the potential role of these genes in NMR. The detected novel CYP2A6 variants explain a strikingly large fraction of variance (up to 31%) in NMR in the current sample, suggesting that they tag both known and unidentified functional variants. The population-attributable effect of the detected independent variants is thus far greater than that of the four functional variants frequently genotyped in Caucasians (CYP2A6*2, *4, *9, and *12). Further, we enclose evidence for plausible epigenetic mechanisms on 19q13. 2 influencing NMR.
Nicotine metabolism rate significantly varies between individuals and affects smoking behavior. Individuals with fast nicotine metabolism typically smoke more and thus have a greater risk for smoking-induced diseases. Further, the efficacy of smoking cessation pharmacotherapy is dependent on nicotine metabolism rate. Twin and family studies have shown that genes influence nicotine metabolism; however, only a minor fraction of variance in inter-individual differences in nicotine metabolism is accounted for by known reduced activity variants in CYP2A6, the main metabolic enzyme for nicotine. Here we utilized a biomarker of nicotine metabolism (nicotine metabolite ratio, NMR) in a genome-wide association study of three Finnish cohorts to identify novel genetic variants influencing nicotine metabolism rate. Our results enclose three independent novel signals in CYP2A6. The detected variants explain a strikingly large fraction of variance (up to 31%) in NMR in the study samples. A genetic risk score constructed using the independent signals predicts smoking quantity in two independent Finnish samples. Further, we enclose evidence for plausible epigenetic mechanisms influencing NMR. With the advent of other nicotine delivery devices than tobacco, such as e-cigarettes, the need to understand the long-term consequences and action mechanisms of nicotine and its metabolism are of high public health relevance.
A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism